Use of novel proteosome inhibitors as a therapeutic strategy in lymphomas current experience and emerging concepts

Simple item page
dc.contributor.authorAbayomi, E. A.
dc.contributor.authorSissolak, G.
dc.contributor.authorJacobs, P.
dc.date.accessioned2011-05-15T16:18:16Z
dc.date.available2011-05-15T16:18:16Z
dc.date.issued2007
dc.description.abstractPrecedent from preclinical experiments coupled with two pivotal phase 2 studies in myeloma has focused attention on a potential role for ubiquitin-proteasome pathway in modulating a number of events that occur commonly in the neoplastic process involving proteins in the regulation of cells cycling, growth and differentiation. This influence is vested in the proteasomes which are large complexes of proteolytic enzymes responsible for degradation of many of these intracellular messengers. Logically interest has centred on molecules having the capacity to influence, by degradation, such molecules and although a number of agents are in development bortezomib is the only one currently in clinical use. Velcade, formerly PS-341, is a novel dipeptide boronic acid capable of reversibly inhibiting the 26S proteasome through a range of activities. The latter are anti-proliferative and proapoptotic with the latter blocking nuclear transcription via NF-κ B in addition to down regulating adhesion and inhibiting angiogenesis. Additional changes are mediated in protein folding within the endoplasmic reticulum and contribute to cell death. These concepts are given focus by considering their introduction into treatment of lymphoreticular malignancy. © 2007.
dc.description.versionArticle
dc.identifier.citationTransfusion and Apheresis Science
dc.identifier.citation37
dc.identifier.citation1
dc.identifier.issn14730502
dc.identifier.other10.1016/j.transci.2007.04.009
dc.identifier.urihttp://hdl.handle.net/10019.1/14580
dc.subjectbortezomib
dc.subjectdexamethasone
dc.subjectDNA
dc.subjectI kappa B
dc.subjectimmunoglobulin enhancer binding protein
dc.subjectproteasome inhibitor
dc.subjectprotein p53
dc.subjectrituximab
dc.subjectvascular cell adhesion molecule 1
dc.subjectvasculotropin
dc.subjectarticle
dc.subjectB cell lymphoma
dc.subjectbacterial pneumonia
dc.subjectcandidiasis
dc.subjectcarcinogenesis
dc.subjectcell cycle
dc.subjectcell death
dc.subjectcell differentiation
dc.subjectcell growth
dc.subjectendoplasmic reticulum
dc.subjectfatigue
dc.subjectherpes zoster
dc.subjecthuman
dc.subjecthyponatremia
dc.subjectlarge cell lymphoma
dc.subjectlymphoma
dc.subjectmultiple myeloma
dc.subjectnatural killer cell
dc.subjectnonhodgkin lymphoma
dc.subjectperipheral neuropathy
dc.subjectpositron emission tomography
dc.subjectT lymphocyte
dc.subjectthrombocytopenia
dc.subjectvasculitis
dc.subjectActive Transport, Cell Nucleus
dc.subjectApoptosis
dc.subjectBoronic Acids
dc.subjectCell Adhesion
dc.subjectCell Cycle
dc.subjectCell Differentiation
dc.subjectClinical Trials, Phase II as Topic
dc.subjectEndoplasmic Reticulum
dc.subjectHumans
dc.subjectLymphoma
dc.subjectNeoplasm Proteins
dc.subjectNeovascularization, Pathologic
dc.subjectNF-kappa B
dc.subjectProtease Inhibitors
dc.subjectProteasome Endopeptidase Complex
dc.subjectPyrazines
dc.subjectUbiquitin
dc.titleUse of novel proteosome inhibitors as a therapeutic strategy in lymphomas current experience and emerging concepts
dc.typeArticle
Files
Collections
Stellenbosch University - Scopus Tygerberg Hospital Publications